Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.
Identifieur interne : 000E75 ( PubMed/Curation ); précédent : 000E74; suivant : 000E76Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.
Auteurs : T D L. Steeves [Canada] ; J. Miyasaki ; M. Zurowski ; A E Lang ; G. Pellecchia ; T. Van Eimeren ; P. Rusjan ; S. Houle ; A P StrafellaSource :
- Brain : a journal of neurology [ 1460-2156 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Carbon Radioisotopes, Case-Control Studies, Corpus Striatum (diagnostic imaging), Corpus Striatum (secretion), Dopamine (analysis), Dopamine (secretion), Dopamine Antagonists (therapeutic use), Female, Gambling (psychology), Humans, Male, Middle Aged, Parkinson Disease (diagnostic imaging), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Positron-Emission Tomography, Protein Binding, Raclopride (therapeutic use).
- MESH :
- chemical , analysis : Dopamine.
- chemical , secretion : Dopamine.
- chemical , therapeutic use : Dopamine Antagonists, Raclopride.
- chemical : Carbon Radioisotopes.
- diagnostic imaging : Corpus Striatum, Parkinson Disease.
- physiopathology : Parkinson Disease.
- psychology : Gambling, Parkinson Disease.
- secretion : Corpus Striatum.
- Aged, Analysis of Variance, Case-Control Studies, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Protein Binding.
Abstract
Pathological gambling is an impulse control disorder reported in association with dopamine agonists used to treat Parkinson's disease. Although impulse control disorders are conceptualized as lying within the spectrum of addictions, little neurobiological evidence exists to support this belief. Functional imaging studies have consistently demonstrated abnormalities of dopaminergic function in patients with drug addictions, but to date no study has specifically evaluated dopaminergic function in Parkinson's disease patients with impulse control disorders. We describe results of a [(11)C] raclopride positron emission tomography (PET) study comparing dopaminergic function during gambling in Parkinson's disease patients, with and without pathological gambling, following dopamine agonists. Patients with pathological gambling demonstrated greater decreases in binding potential in the ventral striatum during gambling (13.9%) than control patients (8.1%), likely reflecting greater dopaminergic release. Ventral striatal bindings at baseline during control task were also lower in patients with pathological gambling. Although prior imaging studies suggest that abnormality in dopaminergic binding and dopamine release may be markers of vulnerability to addiction, this study presents the first evidence of these phenomena in pathological gambling. The emergence of pathological gambling in a number of Parkinson's disease patients may provide a model into the pathophysiology of this disorder.
DOI: 10.1093/brain/awp054
PubMed: 19346328
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E75
Links to Exploration step
pubmed:19346328Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.</title><author><name sortKey="Steeves, T D L" sort="Steeves, T D L" uniqKey="Steeves T" first="T D L" last="Steeves">T D L. Steeves</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, UHN, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, UHN, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J" last="Miyasaki">J. Miyasaki</name></author><author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M" last="Zurowski">M. Zurowski</name></author><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name></author><author><name sortKey="Pellecchia, G" sort="Pellecchia, G" uniqKey="Pellecchia G" first="G" last="Pellecchia">G. Pellecchia</name></author><author><name sortKey="Van Eimeren, T" sort="Van Eimeren, T" uniqKey="Van Eimeren T" first="T" last="Van Eimeren">T. Van Eimeren</name></author><author><name sortKey="Rusjan, P" sort="Rusjan, P" uniqKey="Rusjan P" first="P" last="Rusjan">P. Rusjan</name></author><author><name sortKey="Houle, S" sort="Houle, S" uniqKey="Houle S" first="S" last="Houle">S. Houle</name></author><author><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A P" last="Strafella">A P Strafella</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19346328</idno><idno type="pmid">19346328</idno><idno type="doi">10.1093/brain/awp054</idno><idno type="wicri:Area/PubMed/Corpus">000E75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E75</idno><idno type="wicri:Area/PubMed/Curation">000E75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.</title><author><name sortKey="Steeves, T D L" sort="Steeves, T D L" uniqKey="Steeves T" first="T D L" last="Steeves">T D L. Steeves</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, UHN, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, UHN, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J" last="Miyasaki">J. Miyasaki</name></author><author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M" last="Zurowski">M. Zurowski</name></author><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A E" last="Lang">A E Lang</name></author><author><name sortKey="Pellecchia, G" sort="Pellecchia, G" uniqKey="Pellecchia G" first="G" last="Pellecchia">G. Pellecchia</name></author><author><name sortKey="Van Eimeren, T" sort="Van Eimeren, T" uniqKey="Van Eimeren T" first="T" last="Van Eimeren">T. Van Eimeren</name></author><author><name sortKey="Rusjan, P" sort="Rusjan, P" uniqKey="Rusjan P" first="P" last="Rusjan">P. Rusjan</name></author><author><name sortKey="Houle, S" sort="Houle, S" uniqKey="Houle S" first="S" last="Houle">S. Houle</name></author><author><name sortKey="Strafella, A P" sort="Strafella, A P" uniqKey="Strafella A" first="A P" last="Strafella">A P Strafella</name></author></analytic><series><title level="j">Brain : a journal of neurology</title><idno type="eISSN">1460-2156</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Carbon Radioisotopes</term><term>Case-Control Studies</term><term>Corpus Striatum (diagnostic imaging)</term><term>Corpus Striatum (secretion)</term><term>Dopamine (analysis)</term><term>Dopamine (secretion)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Female</term><term>Gambling (psychology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Positron-Emission Tomography</term><term>Protein Binding</term><term>Raclopride (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="secretion" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Antagonists</term><term>Raclopride</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Carbon Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Gambling</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="secretion" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Positron-Emission Tomography</term><term>Protein Binding</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pathological gambling is an impulse control disorder reported in association with dopamine agonists used to treat Parkinson's disease. Although impulse control disorders are conceptualized as lying within the spectrum of addictions, little neurobiological evidence exists to support this belief. Functional imaging studies have consistently demonstrated abnormalities of dopaminergic function in patients with drug addictions, but to date no study has specifically evaluated dopaminergic function in Parkinson's disease patients with impulse control disorders. We describe results of a [(11)C] raclopride positron emission tomography (PET) study comparing dopaminergic function during gambling in Parkinson's disease patients, with and without pathological gambling, following dopamine agonists. Patients with pathological gambling demonstrated greater decreases in binding potential in the ventral striatum during gambling (13.9%) than control patients (8.1%), likely reflecting greater dopaminergic release. Ventral striatal bindings at baseline during control task were also lower in patients with pathological gambling. Although prior imaging studies suggest that abnormality in dopaminergic binding and dopamine release may be markers of vulnerability to addiction, this study presents the first evidence of these phenomena in pathological gambling. The emergence of pathological gambling in a number of Parkinson's disease patients may provide a model into the pathophysiology of this disorder.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19346328</PMID><DateCreated><Year>2009</Year><Month>05</Month><Day>07</Day></DateCreated><DateCompleted><Year>2009</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>Pt 5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.</ArticleTitle><Pagination><MedlinePgn>1376-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awp054</ELocationID><Abstract><AbstractText>Pathological gambling is an impulse control disorder reported in association with dopamine agonists used to treat Parkinson's disease. Although impulse control disorders are conceptualized as lying within the spectrum of addictions, little neurobiological evidence exists to support this belief. Functional imaging studies have consistently demonstrated abnormalities of dopaminergic function in patients with drug addictions, but to date no study has specifically evaluated dopaminergic function in Parkinson's disease patients with impulse control disorders. We describe results of a [(11)C] raclopride positron emission tomography (PET) study comparing dopaminergic function during gambling in Parkinson's disease patients, with and without pathological gambling, following dopamine agonists. Patients with pathological gambling demonstrated greater decreases in binding potential in the ventral striatum during gambling (13.9%) than control patients (8.1%), likely reflecting greater dopaminergic release. Ventral striatal bindings at baseline during control task were also lower in patients with pathological gambling. Although prior imaging studies suggest that abnormality in dopaminergic binding and dopamine release may be markers of vulnerability to addiction, this study presents the first evidence of these phenomena in pathological gambling. The emergence of pathological gambling in a number of Parkinson's disease patients may provide a model into the pathophysiology of this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steeves</LastName><ForeName>T D L</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre, Toronto Western Hospital, UHN, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zurowski</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Pellecchia</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Van Eimeren</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rusjan</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>64423</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>430K3SOZ7G</RegistryNumber><NameOfSubstance UI="D020891">Raclopride</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 1996;4(1):58-73</RefSource><PMID Version="1">20408186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2006 Aug;9(8):1050-6</RefSource><PMID Version="1">16829955</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Dec;13(8):516-9</RefSource><PMID Version="1">17544807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2004 Apr 28;24(17):4105-12</RefSource><PMID Version="1">15115805</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Learn Mem. 2002 Nov;78(3):610-24</RefSource><PMID Version="1">12559839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008;3(6):e2479</RefSource><PMID Version="1">18575579</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Spectr. 2006 Dec;11(12):924-30</RefSource><PMID Version="1">17146406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2001 Aug 15;21(16):RC159</RefSource><PMID Version="1">11459880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Oct 10;67(7):1254-7</RefSource><PMID Version="1">16957130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2001 Sep;21(9):1034-57</RefSource><PMID Version="1">11524609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2006 Sep;12(6):392-5</RefSource><PMID Version="1">16730214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2006 Jun 14;26(24):6583-8</RefSource><PMID Version="1">16775146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2003 Oct;2(10):595-604</RefSource><PMID Version="1">14505581</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74</RefSource><PMID Version="1">9122236</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 1998 Sep;93(9):1375-84</RefSource><PMID Version="1">9926543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2007 Feb;64(2):212-6</RefSource><PMID Version="1">17296836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2005 Sep;11(6):381-6</RefSource><PMID Version="1">16109498</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 1997 Jan;92(1):75-87</RefSource><PMID Version="1">9060199</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Psychol. 2003;54:25-53</RefSource><PMID Version="1">12185211</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2000 Mar;25(3):515-32</RefSource><PMID Version="1">10774721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 1993 Apr;13(4):350-6</RefSource><PMID Version="1">8480281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2002 Jul;27(1):35-46</RefSource><PMID Version="1">12062905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Mar 15;22(4):590-1</RefSource><PMID Version="1">17230484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 1989 Sep 22;168(3):291-8</RefSource><PMID Version="1">2573533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 1993 Jun;14(2):169-77</RefSource><PMID Version="1">8101394</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Aug;131(Pt 8):2094-105</RefSource><PMID Version="1">18577547</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2005 Nov;8(11):1481-9</RefSource><PMID Version="1">16251991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2004 Jan;29(1):195-207</RefSource><PMID Version="1">14571257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1998 May 21;393(6682):266-8</RefSource><PMID Version="1">9607763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2002 Nov;46(2):79-82</RefSource><PMID Version="1">12211085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 1999 Sep;89(9):1369-76</RefSource><PMID Version="1">10474555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 2000 Aug;95 Suppl 2:S91-117</RefSource><PMID Version="1">11002906</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2005 Apr;53(4):695-9</RefSource><PMID Version="1">15817019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 2005 Sep;62(9):1015-21</RefSource><PMID Version="1">16143733</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Dec;21(12):2206-8</RefSource><PMID Version="1">17013907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2000 Sep;12(3):245-56</RefSource><PMID Version="1">10944407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2008 Oct 1;42(4):1537-43</RefSource><PMID Version="1">18598772</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1995;56 Suppl 4:3-6; discussion 53-5</RefSource><PMID Version="1">7713863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1992 Mar;149(3):318-27</RefSource><PMID Version="1">1536268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2007 Mar 2;315(5816):1267-70</RefSource><PMID Version="1">17332411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Nov 22;65(10):1570-4</RefSource><PMID Version="1">16301483</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2003 Nov;110(11):1289-301</RefSource><PMID Version="1">14628193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1995;56 Suppl 4:7-12; discussion 13</RefSource><PMID Version="1">7713866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Apr;19(4):397-405</RefSource><PMID Version="1">15077237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2006 Jul;63(7):969-73</RefSource><PMID Version="1">16831966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Dec;21(12):2068-72</RefSource><PMID Version="1">17044068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Apr;21(4):524-9</RefSource><PMID Version="1">16261618</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 1996 Dec;4(3 Pt 1):153-8</RefSource><PMID Version="1">9345505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 May;59(5):852-8</RefSource><PMID Version="1">16557571</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 2006 Sep;101 Suppl 1:142-51</RefSource><PMID Version="1">16930171</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Jun 13;66(11):1750-2</RefSource><PMID Version="1">16769956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2007 Nov;64(11):1575-9</RefSource><PMID Version="1">17998440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Pharmacol. 2008 Jan 1;75(1):266-322</RefSource><PMID Version="1">17764663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2005 Feb;8(2):147-8</RefSource><PMID Version="1">15643429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychol Med. 1997 Mar;27(2):473-5</RefSource><PMID Version="1">9089839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 1997 Nov;6(4):279-87</RefSource><PMID Version="1">9417971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2003 Jun;160(6):1041-52</RefSource><PMID Version="1">12777258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2001 Nov 2;294(5544):980-2</RefSource><PMID Version="1">11691967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2002 Jan 22;128(2):189-203</RefSource><PMID Version="1">11796164</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2006 Feb;63(2):298</RefSource><PMID Version="1">16476827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2003 Mar;23(3):285-300</RefSource><PMID Version="1">12621304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 1999 Oct;146(4):373-90</RefSource><PMID Version="1">10550488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Dec;13(8):535-6</RefSource><PMID Version="1">17270485</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2004;47 Suppl 1:3-13</RefSource><PMID Version="1">15464121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008;3(1):e1506</RefSource><PMID Version="1">18231593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Pharmacol. 2007 Feb;7(1):69-76</RefSource><PMID Version="1">17174602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Mol Med. 2006 Dec;12(12):559-66</RefSource><PMID Version="1">17070107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jan 23;68(4):301-3</RefSource><PMID Version="1">17242339</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2004 Apr 7;24(14):3554-62</RefSource><PMID Version="1">15071103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comput Assist Tomogr. 1993 Jul-Aug;17(4):536-46</RefSource><PMID Version="1">8331222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 2002 Dec 20;13(18):2499-503</RefSource><PMID Version="1">12499856</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 May;78(5):517-9</RefSource><PMID Version="1">17210626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 2005 Aug;162(8):1403-13</RefSource><PMID Version="1">16055761</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000557" MajorTopicYN="N">secretion</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000557" MajorTopicYN="Y">secretion</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005715" MajorTopicYN="N">Gambling</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020891" MajorTopicYN="N">Raclopride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">CAMS2369</OtherID><OtherID Source="NLM">PMC3479148</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19346328</ArticleId><ArticleId IdType="pii">awp054</ArticleId><ArticleId IdType="doi">10.1093/brain/awp054</ArticleId><ArticleId IdType="pmc">PMC3479148</ArticleId><ArticleId IdType="mid">CAMS2369</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19346328
|texte= Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19346328" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |